The Only Korean Company Selected in the Biotechnology and Healthcare Sector Among Nine Honorees
Expanding Global Pharmaceutical Partnerships With Proprietary AI-Driven Protein Design Platform;
Cumulative Investment Reaches Approximately 70 Billi

On August 26, the artificial intelligence (AI) drug development company Galaxy announced that it has been listed in the ‘Forbes Asia 100 to Watch 2026’, selected by Forbes.

Promotional image for Galaxy's selection in the 'Forbes Asia 100 Best Companies'. Galaxy

Promotional image for Galaxy's selection in the 'Forbes Asia 100 Best Companies'. Galaxy

View original image

The Forbes Asia 100 to Watch is a list that selects unlisted companies in the Asia-Pacific region with innovative business models and high market growth potential. This year, nine companies from Korea, including Galaxy, were selected. In the biotechnology and healthcare sectors, Galaxy is the only company to make the list.


Forbes highlighted Galaxy’s proprietary protein design AI technology and business achievements. The company is conducting joint research with partner companies, including global pharmaceutical firms such as AstraZeneca and Boehringer Ingelheim. Key milestones include raising a cumulative investment of approximately 70 billion won, including a Series B investment earlier this year.


Galaxy is designing and developing antibody and protein therapeutic candidates based on its in-house developed protein design AI platform ‘GalaxyDesign’. By combining an understanding of the physicochemical principles of proteins with AI technology, the company employs a de novo approach, designing protein structures and sequences from scratch with desired functions and properties.


Recently, Galaxy has been expanding joint research and new drug development projects with domestic and international pharmaceutical companies, while also applying its technology to the development of its own new drug pipeline. The AI-designed PD-1/IL-18v bispecific antibody immuno-oncology drug candidate was selected this year as a new assignment for the National New Drug Development Project candidate stage.



Park Taeyong, CEO of Galaxy, said, “This selection signifies recognition of Galaxy’s accumulated AI protein design technology and its proven potential,” and added, “We will continue to grow as a next-generation biotech company that contributes to the development of innovative therapeutics, not only in Asia but also in the global market.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing